Aegerion Pharmaceuticals, Inc.  

(Public, NASDAQ:AEGR)   Watch this stock  
Find more results for AEGR
1.82
+0.09 (5.20%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.65 - 1.84
52 week 1.57 - 20.45
Open 1.74
Vol / Avg. 809,570.00/795,538.00
Mkt cap 56.49M
P/E     -
Div/yield     -
EPS -4.21
Shares 29.50M
Beta 0.67
Inst. own 106%
Aug 3, 2016
Q2 2016 Aegerion Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 28, 2016
Aegerion Pharmaceuticals Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
Jun 24, 2016
Aegerion Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
May 16, 2016
Q1 2016 Aegerion Pharmaceuticals Inc Earnings Call
May 16, 2016
Q1 2016 Aegerion Pharmaceuticals Inc Earnings Release
Mar 9, 2016
Aegerion Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -183.54% -30.57%
Operating margin -164.72% -18.84%
EBITD margin - -9.67%
Return on average assets -63.01% -17.33%
Return on average equity -311.12% -53.17%
Employees 318 -
CDP Score - -

Address

1 Main St Ste 800
CAMBRIDGE, MA 02142-1531
United States - Map
+1-617-5007867 (Phone)
+1-617-9457968 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).

Officers and directors

Sandford D. Smith Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Mary T. Szela Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Gregory D. Perry Chief Financial and Administrative Officer
Age: 54
Bio & Compensation  - Reuters
Anne Marie Cook Senior Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
William Andrews Senior Vice President - Business Development
Age: 50
Bio & Compensation  - Reuters
Martha Carter Senior Vice President, Chief Regulatory Officer
Age: 62
Bio & Compensation  - Reuters
David Aubuchon Chief Accounting Officer
Bio & Compensation  - Reuters
Donald K. Stern Esq. Director
Bio & Compensation  - Reuters
Sol J. Barer Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Antonio M. Gotto Jr., M.D.,Ph.D Independent Director
Age: 79
Bio & Compensation  - Reuters